Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance

Author:  ["Mihai G Netea","Leo A B Joosten","Eli Lewis","Dalan R Jensen","Peter J Voshol","Bart Jan Kullberg","Cees J Tack","Han van Krieken","Soo-Hyun Kim","Anton F Stalenhoef","Fons A van de Loo","Ineke Verschueren","Leslie Pulawa","Shizuo Akira","Robert H Eckel","Charles A Dinarello","Wim van den Berg","Jos W M van der Meer"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Here we report the presence of hyperphagia, obesity and insulin resistance in knockout mice deficient in IL-18 or IL-18 receptor, and in mice transgenic for expression of IL-18 binding protein. Obesity of Il18−/− mice resulted from accumulation of fat tissue based on increased food intake. Il18−/− mice also had hyperinsulinemia, consistent with insulin resistance and hyperglycemia. Insulin resistance was secondary to obesity induced by increased food intake and occurred at the liver level as well as at the muscle and fat-tissue level. The molecular mechanisms responsible for the hepatic insulin resistance in the Il18−/− mice involved an enhanced expression of genes associated with gluconeogenesis in the liver of Il18−/− mice, resulting from defective phosphorylation of STAT3. Recombinant IL-18 (rIL-18) administered intracerebrally inhibited food intake. In addition, rIL-18 reversed hyperglycemia in Il18−/− mice through activation of STAT3 phosphorylation. These findings indicate a new role of IL-18 in the homeostasis of energy intake and insulin sensitivity.

Cite this article

Netea, M., Joosten, L., Lewis, E. et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 12, 650–656 (2006). https://doi.org/10.1038/nm1415

View full text

>> Full Text:   Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance

The autoimmune regulator (Aire) controls iNKT cell development and maturation

Genetic model of selective COX2 inhibition reveals novel heterodimer signaling